Abstract
We estimated the potential benefits of advancing the first dose of pertussis vaccine for infants from 8 to 6 weeks of age, using Australian national disease databases. Infants had notification rates 3-fold greater than the general population and accounted for 52% of recorded hospitalizations. Infants 1 and 2 months of age had notification rates 3.5 times (95% CI: 2.7-4.5) higher than infants 3 to 11 months of age. Estimation of acceleration of the vaccine to 6 weeks of age reduced average notifications, hospitalizations, and hospital bed-days by 8%, 9%, and 12%, respectively, with larger reductions in an epidemic year.
Original language | English |
---|---|
Pages (from-to) | 161-163 |
Number of pages | 3 |
Journal | Pediatric Infectious Disease Journal |
Volume | 30 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2011 |